Shree Ganesh Remedies posts mixed results, navigates market softness with strategic growth

Shree Ganesh Remedies Limited reported a 6% year-on-year decline in revenue from operations to ₹30.32 crores in Q2 FY26, and a 4% decline to ₹54.98 crores for H1 FY26. EBITDA (excluding OI & EI) for Q2 FY26 was ₹9.62 crores, down 15% year-on-year, while H1 FY26 saw a 13% decrease to ₹16.92 crores. PAT for Q2 FY26 stood at ₹4.93 crores, a 23% year-on-year decrease, with H1 FY26 PAT at ₹8.37 crores, down 24%. Despite these declines, the company maintained EBITDA margins in the 24-26% range.

The company is progressing with significant capital expenditures. A new pilot facility is nearing commissioning, with operations expected to begin in Q4 FY26. Block 7 is planned to be operational by H2 FY27, and the newly commissioned Block 8 is targeted to achieve 50-60% utilization by the end of the current financial year. An investment of ₹15 crores is projected for FY26 for new manufacturing blocks and R&D initiatives.

In strategic expansion, the company acquired 40,554 sq m of land in Dahej in 2022 for future large-scale projects, with a capital outlay of ₹11 crores. Shree Ganesh Remedies Limited continues to focus on complex and niche specialty chemicals, leveraging its strong R&D capabilities, including a team of 40 members and an ISO-recognized lab.